Kazuhide Nakamura

1.3k citations

27 papers · 1.0k indexed · h-index 18

Oncology top 10%
Molecular Biology
- Angiogenesis and VEGF in Cancer 6
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Tyrosine Phosphatases 3
- Melanoma and MAPK Pathways 3
Cancer Research
- Cancer, Hypoxia, and Metabolism 3
Pharmacology top 10%
Hepatology top 10%
- Liver physiology and pathology 2
Hematology
- Acute Myeloid Leukemia Research 2
Organic Chemistry
- Synthesis and biological activity 2

Co-authors: Masabumi Shibuya Kazuo Kubo Toshiyuki Isoe Eri Taguchi Shinobu Iwai Sachie Hiratsuka Yoichiro Iwakura Mai Yamauchi
Cited by: Oncology Molecular Biology Cancer Research
Journals: Molecular Cancer Therapeutics (4 papers)Bioorganic & Medicinal Chemistry (2 papers)Cancer Science (2 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Kazuhide Nakamura

27 papers receiving 985 citations

Peers

Countries citing papers authored by Kazuhide Nakamura

Since Specialization

Citations

This map shows the geographic impact of Kazuhide Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazuhide Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazuhide Nakamura more than expected).

Fields of papers citing papers by Kazuhide Nakamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazuhide Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazuhide Nakamura. The network helps show where Kazuhide Nakamura may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kazuhide Nakamura, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kazuhide Nakamura Line = papers co-authored together Kazuhide Nakamura links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors Clinical Cancer Research ·Janita A. Maring,Kunihiko Kiyono,E. Wolfendale,L.A. Chekhomova,Mitsuhiro Nishida,Keiji Fujiyoshi,Qiao Y.-J.,大山直雄,Shingo Nishikori,اشرف کاظمی,Yenni Yusuf,Alok Mishra,Kazuhide Nakamura	2024	2
2	Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab Neoplasia ·Hiroya Taniguchi,Yuji Baba,Yoji Sagiya,Bruce K. Trauben,Kazuhide Nakamura,Hiroshi Sawada,Kazunori Yamanaka,Alan T Jim,Ikuo Mori,Débora Lohane Lima Albuquerque,Junpei Soeda,Hideo Baba	2018	7
3	LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B Cancer Research ·Shinji Takagi,Yoshinori Ishikawa,Akio Mizutani,Shinji Iwasaki,Satoru Matsumoto,Yusuke Kamada,Toshiyuki Nomura,Kazuhide Nakamura	2017	66
4	Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication Oncogenesis ·Yoshinori Ishikawa,F Blanc,Megumi Morimoto,Akio Mizutani,Akiko Nakayama,K Toyoshima,Akimasa Hayashi,Iwuagwu Chinonso C,Ryo Dairiki,Hitoshi Miyashita,Shigemitsu Matsumoto,Kanae Gamo,Toshiyuki Nomura,Kazuhide Nakamura	2017	26
5	Panitumumab interaction withTAS‐102 leads to combinational anticancer effects via blocking ofEGFR‐mediated tumor response to trifluridine Molecular Oncology ·Yuji Baba,Toshiya Tamura,Yoshihiko Satoh,Bruce K. Trauben,Hiroshi Sawada,Shunsuke Ebara,Kazunori Shibuya,Junpei Soeda,Kazuhide Nakamura	2017	18
6	A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities Molecular Cancer Therapeutics ·Gianfranco Mieli,Kazuhide Nakamura,Akio Mizutani,도딘롱,Hidehisa Iwata,Seiji Yamasaki,Naoki Miyamoto,Shinichi Imamura,Hiroshi Miki,Ιωάννης Πελεκάνος	2013	27
7	Anti‐angiogenic and anti‐tumor effects of TAK‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine kinase Cancer Science ·Gianfranco Mieli,Akio Mizutani,María Luisa Wic Galván,Nantira Pookhao,Kazuhide Nakamura,도딘롱,Osamu Kitahara,Toshiyuki Takeuchi,Seiji Yamasaki,Naoki Miyamoto,Hidehisa Iwata,Hiroshi Miki,Shinichi Imamura,Akira Hori	2013	16
8	Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors Bioorganic & Medicinal Chemistry ·Shigemitsu Matsumoto,Naoki Miyamoto,Takaharu Hirayama,Hideyuki Oki,Kengo Okada,Michiko Tawada,Hidehisa Iwata,Kazuhide Nakamura,Seiji Yamasaki,Hiroshi Miki,Akira Hori,Shinichi Imamura	2013	48
9	Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model Cancer Science ·Eri Taguchi,Kazuhide Nakamura,Toru Miura,Masabumi Shibuya,Toshiyuki Isoe	2008	28
10	KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties Cancer Research ·Kazuhide Nakamura,Eri Taguchi,Tsuyoshi Miura,Atsushi Yamamoto,Kohei Takahashi,Francis Bichat,Nicolas Guilbaud,Koki Hasegawa,Kazuo Kubo,María V Wolf,R Suzuki,Kin‐ya Kubo,Masabumi Shibuya,A.-C. Bay-Jensen	2006	164
11	Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages Blood ·Masato Murakami,Shinobu Iwai,Sachie Hiratsuka,Mai Yamauchi,Kazuhide Nakamura,Yoichiro Iwakura,Masabumi Shibuya	2006	147
12	Altered expression of topoisomerase IIα contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation British Journal of Cancer ·Takeshi Asano,Kazuhide Nakamura,Hisaki Fujii,Naoya Horichi,Tohru Ohmori,Kunihiro Hasegawa,Toshiyuki Isoe,Mitsuru Adachi,NOBORU OTAKE,Yoshitaka Fukunaga	2005	18
13	Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureas Journal of Medicinal Chemistry ·Kazuo Kubo,Toshiyuki Shimizu,Tianqi Chen,Hideko Murooka,峰陈,Kazuhide Nakamura,Kazumasa Hasegawa,Yoshiko Kobayashi,Noriko Takahashi,Kazumi Takahashi,Shinichiro Kato,Toshio Izawa,Toshiyuki Isoe	2005	131
14	Synthesis and structure–activity relationship for new series of 4-Phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase Bioorganic & Medicinal Chemistry ·Kazuo Kubo,Tianqi Chen,Toshiyuki Shimizu,谭春鸿,Hideko Murooka,Tsuyoshi Nishitoba,Shinichiro Kato,Mikio Yagi,Yoshiko Kobayashi,А С Акулова,Toshiyuki Isoe,Kazuhide Nakamura,Hiroshi Iijima,Tatsushi Osawa,Toshio Izawa	2003	19
15	Synthesis and structure-activity relationship of Quinazoline-Urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors Kazuo Kubo,Yutaka Fujiwara,S. H Zeng,Hideko Murooka,Hongpeng Ruan,Kazuhide Nakamura,Koki Hasegawa,Yoshiko Kobayashi,Naoko Takahashi,Kohei Takahashi,Masabumi Shibuya,D. Cairol,Toshiyuki Isoe	2002	1
16	Abortive assembly of succinate-ubiquinone reductase (Complex II) in a ferrochelatase-deficient mutant of Escherichia coli Molecular Genetics and Genomics ·Anantha N.R. Kollengode,Toru Nakayashiki,Kazuhide Nakamura,Hachiro Inokuchi,Robert B. Gennis,Satoshi Kojima,Kiyoshi Kita	2001	21
17	Selective Inhibition of Platelet-Derived Growth Factor (PDGF) Receptor Autophosphorylation and PDGF-Mediated Cellular Events by a Quinoline Derivative Experimental Cell Research ·Mikio Yagi,Shinichiro Kato,Yoshiko Kobayashi,Kazuo Kubo,Youngjae Choe,Toshiyuki Shimizu,Tsuyoshi Nishitoba,Toshiyuki Isoe,Kazuhide Nakamura,邱俊達,Glenn Robert,А С Акулова,Tatsushi Osawa,Rie Onose,Jordan Jay Hillman	1997	15
18	Significant contribution of arginine-112 and its positive charge of Pseudomonas putida cytochrome P-450cam in the electron transport from putidaredoxin Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology ·Kazuhide Nakamura,Tadao Horiuchi,Takanori Yasukochi,Kazuhisa Sekimizu,Takayuki Hara,Yasuhiro Sagara	1994	37
19	Essential role of the Arg¹¹² residue of cytochrome P450cam for electron transfer from reduced putidaredoxin FEBS Letters ·Hideo Koga,Yasuhiro Sagara,Fouakeu-Tatieze Stéphane,Mitsushi Tsujimura,Kazuhide Nakamura,Kazuhisa Sekimizu,Ryu Makino,Hideo Shimada,Yuzuru Ishimura,Kei Yura,Mitiko Gō,Masamichi Ikeguchi,Tadao Horiuchi	1993	58
20	Amino acid sequence of polypeptide chain IIB of extracellular hemoglobin from the polychaete Tylorrhynchus heterochaetus. Journal of Biological Chemistry ·Toshiaki Suzuki,FREDERICO CLÁUDIO PEIXINHO,Takahiro Furukohri,Kazuhide Nakamura,Toshio Gotoh	1985	21

About Kazuhide Nakamura

Kazuhide Nakamura is a scholar working on Immunology and Allergy, Oncology and Molecular Biology, having authored 27 papers that have together received 1.0k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer, Hypoxia, and Metabolism (3 papers), Protein Tyrosine Phosphatases (3 papers), Melanoma and MAPK Pathways (3 papers), Acute Myeloid Leukemia Research (2 papers), Synthesis and biological activity (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Oncology (249 citations), Molecular Biology (601 citations) and Cancer Research (130 citations). Kazuhide Nakamura has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Masabumi Shibuya, Kazuo Kubo, Toshiyuki Isoe, Eri Taguchi, Shinobu Iwai, Sachie Hiratsuka, Yoichiro Iwakura, Mai Yamauchi, Masato Murakami and Kazumi Takahashi. Their work appears in journals such as Molecular Cancer Therapeutics, Bioorganic & Medicinal Chemistry, Cancer Science, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact